AUCATZYL® Product Handling Manual (US)

US-AUC-0077

Table of Contents

Introduction

This **Manual** provides guidance on the steps involved in the distribution of AUCATZYL® (obecabtagene autoleucel) drug product to a hospital site, instructions for receipt, transfer to local vapor-phase nitrogen storage, handling, thaw and infusion. It is essential for drug product to be handled correctly at each stage of the process to ensure integrity and patient safety.

This manual does not describe the handling, storage, and administration of other agents administered in conjunction with AUCATZYL® drug product (e.g., pre-conditioning chemotherapy). Please consult the AUCATZYL® US Prescribing Information for information regarding concomitant therapies.

Guidance on leukapheresis procurement and the management, traceability, packaging, and shipping of a patient's cells to an Autolus manufacturing facility is provided in the **Autolus AUCATZYL® US Apheresis Manual**.

Compliance with local quality standards and the Autolus Master Agreement must be maintained.

It is vital that the Center provides Autolus with current correct contact details and addresses to ensure safe handling of leukapheresis material and AUCATZYL® product. These details are collected via the **Apheresis and Treatment Center Setup Form** and **Qualification Survey** during onboarding.

Transport of AUCATZYL® drug products, including import and export are managed by Autolus using the designated courier.

Chain of Identity

Autolus uses a Cell Orchestration Platform, known as the **AutolusAssist™ Scheduling Portal**, to manage the Patient Cell Journey and act as a system of record for Chain of Identity (COI) and Chain of Custody (COC).

To ensure traceability of a patient's cells Autolus uses a unique identifier, the **Chain of Identity Identifier (COI ID)**. The COI ID is generated following patient registration in the AutolusAssist™ Scheduling Portal.

Patient Full Name, Date of Birth, Patient Hospital ID and an apheresis identifier (ISBT128 DIN or locally defined identifier) are additional identifiers to ensure maintenance of the vein-to-vein Chain of Identity. The COI ID and additional patient identifiers are applied to the leukapheresis collection bag and will be present on the final drug product label.

Full patient identifiers are maintained securely in the AutolusAssist™ Scheduling Portal and are only present on the leukapheresis label and final drug product labels. In the event of any potential, suspected or actual data breach, please notify AutolusAssist™ (scheduling@autolus.com **Tel. 1-855-288-5227**) as soon as possible and in any event within 24 hours.

Responsibilities

Instructions in this manual are designed to enable compliance with legal and regulatory requirements and seamless operation of the Autolus supply chain.

The prescribing physician is responsible for determining patient readiness for leukapheresis and treatment with AUCATZYL® and obtaining appropriate consent.

The Apheresis Collection Center or Authorized Treatment Center must adhere to the Compliance Requirements detailed in the Autolus Apheresis Quality Agreement and notify Autolus without delay of any changes/events/issues that may impact that agreement.

Autolus will ensure that suitable training is provided prior to Apheresis Collection or Treatment Center activation. A requirement for follow-up or additional training may be identified by Autolus or the Center to ensure compliance and quality requirements are met.

AutolusAssist™

Autolus has a dedicated team of experts providing support 24/7 all year round.

For assistance please call:
AutolusAssist™: Tel. 1-855-288-5227

AutolusAssist™ Case Managers are the primary point of contact and will be able to assist with most enquiries or put you in direct contact with functional specialists where required.

AutolusAssist™ Patient Scheduling and Logistics team arrange, coordinate and track collection of leukapheresis material from the Apheresis Collection Center, delivery to Autolus manufacturing and return of the AUCATZYL® product back to the Authorized Treatment Center for infusion .

Logistics arrangements and milestone updates will be provided by email.

The Autolus Patient Scheduling and Logistics team can be contacted at scheduling@autolus.com.

Autolus Apheresis and Infusion Operations Team

Autolus has a team of field-based experts with experience across apheresis, infusion, and quality assurance. The team will work with you to establish the Autolus autologous cell therapy supply chain and provide technical training and assistance where required. Apheresis and Infusion Managers may be contacted directly or AutolusAssist™.

AutolusAssist™ Scheduling Portal

To manage the pateint cell journey, a web-based Cell Orchestration Platform, also known as the AutolusAssist™ Scheduling Portal, is used. Upon registration of a patient in the Scheduling Portal the center user will be able to view product manufacturing progress and expected delivery date.
Refer to the AutolusAssist™ Scheduling Portal User Guide for detail.

The AutolusAssist™ Scheduling Portal (Product) is required for the following tasks:



Figure 1: Scope of the Product Handling Manual and associated AutolusAssist™ Scheduling Portal tasks.

Product Description

AUCATZYL® is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients (18 years and over) with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL).

AUCATZYL® is prepared from the patient's own peripheral blood mononuclear cells, which are collected via a non-mobilized leukapheresis procedure. The mononuclear cells are enriched for T cells, activated and transduced with a replication-incompetent lentiviral vector containing the CD19 CAR transgene. The transduced T cells are expanded in cell culture, washed, formulated into a suspension, and then cryopreserved.

AUCATZYL® is frozen in patient-specific infusion bag(s) and thawed prior to infusion. The thawed product is a colorless to pale yellow, very opalescent suspension that is essentially free from visible foreign particles. After AUCATZYL® is infused anti CD19 (CAT) CAR-positive T cells can recognize and eliminate CD19-expressing target cells.

AUCATZYL® will also contain non-transduced autologous T cells and cells other than T cells. AUCATZYL® is formulated using phosphate-buffered saline (PBS), Human Serum Albumin (HSA), Ethylenediaminetetraacetic Acid (EDTA) and 7.5% Dimethyl Sulphoxide (DMSO). The number of CD19 CAR-positive viable T cells per infusion bag is described on the accompanying Release for Infusion (RFI) Certificate.

Bag configurations and the Drug Product Bag Label

A colored stripe on the DP label is a bag configuration identifier, designed to assist with the easy identification of the required bag(s) for infusion.

The target dose of 410x10^6 CD19 CAR-positive viable T cells is divided into three different bag configurations: the **Blue** 10x10^6 bag configuration, the **Orange** 100x10^6 bag configuration, and the **Red** 300x10^6 bag configuration.



Figure 2: Example AUCATZYL® product bag label for a) 10x10^6 bag configuration (50mL infusion bag), b) 100x10^6 bag configuration (50mL infusion bag), c) 100x10^6 bag configuration (250mL infusion bag), and d) 300x10^6 bag configuration (250mL infusion bag)



Figure 3: Example AUCATZYL® Patient-specific label

The treatment regimen consists of a split dose infusion to be administered on Day 1 and Day 10 (±2 days). Dose to be administered is determined by the patient bone marrow blast assessment.

Product delivery

Notifications and AUCATZYL® drug product delivery scheduling

Any user with log in credentials can access the Scheduling Portal and view the status of patients at their center. Refer to AutolusAssist™ Scheduling Portal User Guide.

Once AUCATZYL® manufacturing has begun, an email notification from Autolus will inform the Center of an estimated, earliest, AUCATZYL® delivery date. This date will be based on the manufacturing timeline, Quality Batch Release date and shipping time to the Authorized Treatment Center.

Once the AUCATZYL® drug product has harvested, pending release testing and Quality Batch Release, the Authorized Treatment Center will be notified of the planned product delivery date. If this date does not suit the Treatment Center or patient, please contact AutolusAssist™ and we will work with you to reschedule the delivery.

If there is a change to the Quality Batch Release date that impacts the AUCATZYL® delivery date, Autolus will notify the Treatment Center as soon as possible.

The Center will receive an additional notification once the AUCATZYL® drug product has been Quality Batch Released and scheduled for shipping. A Release for Infusion (RFI) certificate will be provided to the Treatment Center via the AutolusAssist™ Scheduling Portal, with a physical copy included in the DP shipper.

These notifications will be sent to the contacts provided in the Apheresis and Treatment Center Setup Form. If you would like to add or remove recipients, please contact AutolusAssist™ scheduling@autolus.com.

AUCATZYL® drug product shipment to Treatment Center

The AUCATZYL® drug product is shipped in a vapor-phase liquid nitrogen (LN_2) shipper that maintains the temperature ≤-150° C. The image below shows an example of the SAVSU DV10 LN_2 shipper for shipping AUCATZYL® drug product from the Autolus manufacturing site to the Authorized Treatment Center.

Autolus has engaged specialist couriers to provide logistics services to ensure appropriate shipping and security of materials throughout the cell journey.

Figure 4 SAVSU DV10 LN2 Shipper and outer packaging (the outer shipper may look different to that pictured)

AUCATZYL® drug product will be delivered to the address at the Authorized Treatment Center that was provided at the time of onboarding.

The return of the empty shipper will be scheduled for 9:00am the day after it was delivered (or Monday if delivery was Friday).

AUCATZYL® drug product receipt

Upon arrival at the Authorized Treatment Center, the delivery of AUCATZYL® drug product requires urgent attention. The designated contact person(s) at the Center must have access to the AutolusAssist™ Scheduling Portal and a copy of the RFI certificate to be able to log receipt of the delivery. Refer to AutolusAssist™ Scheduling Portal User Guide.

Confirm that the shipper has not been tampered with by checking the integrity of the external security tags before initiating the receipt process. To complete the receipt of AUCATZYL® drug product you will also need to access the EVO link provided to review the temperature monitoring and record the temperature reading upon delivery.

If the external security tags are not present or not intact, contact AutolusAssist™ immediately.

Figure 5 SAVSU LN2 shipper outer packaging and external serialized ties

Once the integrity of external security tag (plastic zip tie in Figure 5) is confirmed, remove the external security tag (retaining tag until the serial numbers have been recorded in the Scheduling Portal) and recover the documents within the outer packaging.

DO NOT REMOVE SECURITY TAGS FROM THE SHIPPER LID AT THIS TIME.

The document sleeve will contain:

The Autolus Packing Slip,

a patient-batch-specific Release for Infusion Certificate, and

a patient-specific Dose Schedule Planner

Figure 6 Document sleeve to the front of Smart Cap

Confirm that the Air Waybill (AWB) number and COI number on the AWB match those on the Autolus Packing Slip. Check that the COI ID displayed for the patient in the AutolusAssist™ Scheduling Portal matches exactly with the documentation and enter the AWB number in the Scheduling Portal to proceed to complete the "Receive DP Shipper" tasks.

Verify that the tamper evident seals on the shipper match those logged in the Scheduling Portal, the shipper has been received in good condition and that the temperature has been maintained ≤-150°C. If the temperature is not within specification, contact AutolusAssist™ immediately. **Do not open the shipper if there is any doubt.**

The shipper temperature will be monitored by Autolus while in transit to the Treatment Center. If a temperature excursion is observed during transit the Center will be notified.

In the event of a temperature excursion, **DO NOT USE THE PRODUCT** and contact AutolusAssist™ immediately. The AUCATZYL® drug product unit(s) should be placed into quarantine until Autolus provides further instructions.

Transfer from LN_2 shipper to storage

Upon delivery, AUCATZYL® drug product must be immediately transferred from the LN_2 shipper into a controlled-access vapor phase liquid nitrogen environment for storage ≤-150°C. If it is not possible to transfer the AUCATZYL® drug product to local storage on receipt or a temperature excursion (above -150°C) occurs during transfer into on-site storage, contact AutolusAssist™ immediately.

Receiving personnel at the Authorized Treatment Center will need access to the AutolusAssist™ Scheduling Portal, entering key identifiers from the shipper and drug product labels to confirm receipt and transfer. Refer to AutolusAssist™ Scheduling Portal User Guide.

Figure 7 -ModPak in DV10 LN2 shipper and ModPak being unloaded by personnel in PPE

Transfer Steps:

Figure 8- Smart Cap with security tag

Remove the security tags on the Smart Cap (retaining tag until the serial numbers have been recorded in the AutolusAssist™ Scheduling Portal).

Remove the Smart Cap, taking care not to damage the probe on the underside.

Figure 9 - Opening the ModPak

Remove the ModPak from the shipper and open the ModPak.

Figure 10 - Open ModPak with cassettes

During transfer it is important to only remove one cassette from the ModPak at a time. Place the ModPak back into the shipper, maintaining the remaining cassettes ≤-150°C, and replace the Smart Cap to maintain the internal temperature of the shipper.

Time out of the vapor phase liquid nitrogen environment should be kept to an absolute minimum to avoid premature product thaw (recommend to not exceed 90 seconds).

For each cassette received open the cassette. Confirm the patient identifiers (COI, name, and date of birth) on the bag label match exactly with those in the Scheduling Portal and on the RFI certificate and visually check the integrity of the frozen bag (i.e., no visible cracks or splits).

Keeping the infusion bag in the cassette, transfer to storage and repeat all steps for all other cassettes.

It is important to note where each individual cassette is stored because the cassettes to be removed on the day of administration will vary.

Complete the remaining tasks in the Scheduling Portal confirming drug product receipt and transfer. In case of any issues with drug product bag transfer, temperature, or integrity, contact Autolus immediately.

Retain the patient batch specific Release for Infusion Certificate and air waybill as required by local institutional policy. The Release for Infusion Certificate will be required, along with the Dose Schedule Planner, to determine the correct dosing regimen and dose preparation for infusion.

Preparation for Treatment with AUCATZYL®

A bone marrow sample (trephine core biopsy or fine needle aspirate) must be obtained within 7 days prior to the commencement of the lymphodepleting chemotherapy regimen on Day minus six (Day -6). The bone marrow blast percentage will be used to determine the AUCATZYL® dosing schedule.

All patients will receive a pre-conditioning regimen using fludarabine (FLU) 30 mg/m^2 i.v. over 30 minutes immediately followed by cyclophosphamide (CY) 500 mg/m^2 i.v. over 30 minutes. Fludarabine will be given on Days -6, -5, -4, and -3 (total dose 120 mg/m^2) and CY will be given on Days -6 and -5 (total dose 1000 mg/m^2) before the first dose of AUCATZYL®.

Infuse AUCATZYL® 3 days (±1), ***but no less than 48 hours***, after completion of lymphodepleting chemotherapy treatment (Day 1).



Figure 11 - AUCATZYL® Treatment Schedule

AUCATZYL® Dosage and Schedule

Following lymphodepleting pre-conditioning, patients will receive the tumor-burden guided dose of AUCATZYL® drug product with dose fractions determined by the patient bone marrow blast percentage.

The dose of AUCATZYL® is expressed as the number of CD19 CAR-positive viable T cells. All patients will receive AUCATZYL® as a split dose with a total target dose of 410 x 10^6 CD19 CAR-positive T cells. The first AUCATZYL® infusion will take place on Day 1 followed by the second infusion on Day 10 (±2 days).

Dosing regimens are depicted in Figure 12

Bone Marrow Blast > 20%

Day 1	Day 10 (± 2 days)
10 × 10^6 Dose administered via ***syringe***[a]	**100 × 10^6 Dose** administered via ***bag infusion***[b] and **300 × 10^6 Dose** administered via ***bag infusion***[b]

Bone Marrow Blast ≤ 20%

Day 1	Day 10 (± 2 days)
100 × 10^6 Dose administered via ***bag infusion***[b]	**10 × 10^6 Dose** administered via ***syringe***[a] and **300 × 10^6 Dose** administered via ***bag infusion***[b]

[a] Refer to Release for Infusion Certificate for the exact volume to be administered via syringe. Withdraw **ONLY** the specified volume.
[b] The 100 x 10^6 (Orange Bag) and 300 x 10^6 (Red Bag) doses will be suspended in one or more infusion bags.

Figure 12 - AUCATZYL® Dosage and Schedule

Preparation for Infusion



Autolus

AUCATZYL RELEASE FOR INFUSION CERTIFICATE

Name of Medicinal Product: AUCATZYL 410 x 10^6 cells suspension for infusion. Obecabtagene autoleucel (CAR+ viable T cells). **For autologous use only.**
Statement of Active Substance: Autologous enriched human T cells transduced with a lentiviral vector to express an anti-CD19 chimeric antigen receptor (CAR). This medicine contains human blood cells. Unused medicine or waste material must be disposed of in compliance with the local guidelines on handling of waste of human-derived material. **Ship and store in the vapour phase of liquid nitrogen (≤-150°C). Do not refrigerate or refreeze thawed medicinal product.**
Read the prescribing information before use. Save this document and have it available when preparing for administration of AUCATZYL.

SECTION 1 - PATIENT DETAILS

Chain of Identity (CoI) ID	C	H	G	2	3	4	4	2	4	B	D	A	R	2	8
Donation Identifier	W543224762662														
Patient Hospital ID	44-48-91-1														
Patient First Name, Middle Initial	Mila, G														
Patient Last Name	Wilson														
Date of Birth	2	5	A	P	R	1	9	5	6						

SECTION 2 - PRODUCT BATCH DETAILS AND DOSE INFORMATION

Total Recommended Dose	**410 x 10^6 CD19 CAR-positive viable T cells**

Product Expiry Date	2	8	J	U	N	2	0	2	5

Bag configuration: 10 x 10^6 CD19 CAR-positive viable T cells (Blue bag)

Drug Product Bag Serial Number	**1001-002027-S0001**	
Number of Bags Provided for 10 x 10^6 Dose	1	Bag
Volume per bag	10	mL
Number of CD19 CAR-positive viable T Cells in bag	65	x 10^6
Volume to Administer via Syringe to deliver 10 x 10^6 CD19 CAR-positive viable T Cells	1.54	mL

Bag configuration: 100 x 10^6 CD19 CAR-positive viable T cells (Orange bag)

Drug Product Bag Serial Number(s)	**1001-002027-S0003**	
Number of Bags Required for 100 x 10^6 Dose	1	Bag(s)
Volume per bag	15.4	mL
Number of CD19 CAR-positive viable T Cells in each bag	100	x 10^6
Volume to Administer via infusion	Entire bag(s)	

Bag configuration: 300 x 10^6 CD19 CAR-positive viable T cells (Red bag)

Drug Product Bag Serial Number(s)	**1001-002027-S0005**	
Number of Bags Required for 300 x 10^6 Dose	1	Bag(s)
Volume per bag	46.2	mL
Number of CD19 CAR-positive viable T Cells in each bag	300	x 10^6
Volume to Administer via infusion	Entire bag(s)	

This lot of product has been manufactured, including packaging/labelling and quality control in full compliance with the GMP requirements of the local Regulatory Authority and with the specifications in the Marketing Authorisation.

Qualified Person
Signature

For any urgent query, contact Autolus on 1-855 288-5227
VV-QUAL-08078 v3.0

License Holder: Autolus Inc., Gaithersburg, Maryland 20877, USA
NDC: 83047-410-04

AUCATZYL® must not be prepared for administration until after receipt of the Release for Infusion Certificate (RFI; Figure 13) and confirmation that the bone marrow assessment results are available.

Section 2 of the Release for Infusion Certificate indicates the number of AUCATZYL® drug product bags and/or the volume to administer for each of the individual doses.

Particular attention must be given to the volume required for the syringe delivery of the 10 x 10^6 CD19 CAR-positive T cells dose, as this is typically a small fraction of the total bag volume.

Figure 13 – Example AUCATZYL® Release for Infusion (RFI) Certificate

The Dose Schedule Planner tool (provided via the AutolusAssist™ Scheduling Portal and as a physical copy in the shipper; Figure 14) should be used to determine the appropriate dose schedule based on the pre-lymphodepletion bone marrow blast percentage. Using the Dose Schedule Planner in conjunction with the Release for Infusion Certificate, the Treating physician or delegate should record the bone marrow blast percentage and use this to select the correct regimen and complete product administration details.

IMPORTANT:

If the BM assessment results are inconclusive:

- A repeat biopsy or aspirate must only be taken prior to the initiation of lymphodepleting chemotherapy
- If results remain inconclusive, proceed with the **Regimen for Bone Marrow Blast Percentage >20% (i.e., administration of the 10 x 10^6 dose on Day 1).**



Figure 14 - Example Dose Schedule Planner

Transfer from Storage Area to Thaw Location - Day 1 and Day 10

Timing of AUCATZYL® thaw and infusion need to be carefully coordinated, and it is important to ensure that a minimum of two doses of tocilizumab and emergency equipment are available prior to infusion and during the recovery period.

Once the treating physician has determined the dose schedule, the Release for Infusion Certificate and Dose Schedule Planner will be provided to the staff responsible for selecting the appropriate bag(s) from the controlled-access vapor phase liquid nitrogen storage.

The Release for Infusion Certificate details the volume needed to administer the $10x10^6$ CD19 CAR-positive T cell dose. The completed Dose Schedule Planner will need to be checked by a member of the Cell Lab or Pharmacy team to ensure that the "Volume to Administer" for the $10x10^6$ dose agrees with the details on the Release for Infusion Certificate.

Staff will need to refer to the Release for Infusion Certificate and Dose Schedule Planner for available inventory and to determine which cassette(s) will need to be removed from storage for the Day 1 dose.

If the Day 1 dose is determined to be **$10x10^6$** CAR-positive T cells (BONE MARROW BLAST COUNT >20%) there will be **ONLY one bag for Day 1, which will be used to prepare the syringe infusion**.

If the Day 1 dose is determined to be **$100x10^6$** CAR-positive T cells (BONE MARROW BLAST COUNT ≤20%) there **may be one or more bags for Day 1, which will be infused in their entirety**.

ONLY REMOVE THE BAG(S) FOR THAT SPECIFIC DOSING DAY

Remove the cassette(s) containing the required drug product infusion bag(s) from storage.

ONLY REMOVE THE CASSETTE(S)/BAG(S) FOR THAT SPECIFIC DOSING DAY

Confirm the patient identifiers, Chain of Identity number, and Drug Product Bag Serial number correspond exactly with the details on the Release for Infusion Certificate and transfer the AUCATZYL® drug product cassette(s)to the thaw location using your local cryo transport vessel (maintaining temperature ≤-150°C). The Release for Infusion Certificate and completed Dose Schedule Planner must travel with the drug product.

Thawing and Administration of AUCATZYL®

AUCATZYL® must be administered to patients in accordance with these Autolus AUCATZYL® Product Handling Manual instructions.

Carefully align the timing of AUCATZYL® thaw with patient readiness. Where a multiple bag dose is being administered, only remove, thaw, and infuse one bag at a time.

DO NOT BEGIN THE THAW OF A SECOND BAG UNTIL THE INFUSION OF THE FIRST BAG IS COMPLETE.

DO NOT REFREEZE THAWED MATERIAL.

DO NOT USE A LEUKODEPLETING FILTER.

DO NOT IRRADIATE.

Once at the thaw location (preferably patient's bedside) please complete the following steps:

1. Prior to thaw, at least two trained staff members must verify the patient's identity against the AUCATZYL® drug product bag label.
2. The internal cryo transport vessel should be opened to remove the first cassette containing the first AUCATZYL® drug product bag and closed immediately after removal of the cassette. The same opening and immediate closure process should be followed for subsequent bags if there is more than one bag for this dose.
    - DO NOT REMOVE SUBSEQUENT BAGS UNTIL THE PREVIOUS BAG HAS BEEN ADMINISTERED.
3. Verify Patient identifiers on the cassette and bag label correspond exactly with the intended recipient and verify the visual integrity of bag.
    - If the Patient identifiers don't correspond exactly or bag integrity is compromised contact AutolusAssist™ immediately.
4. Leave the AUCATZYL® infusion bag in its overwrap, thaw at 37°C using a water bath or Autolus Approved dry thaw method until there are no visible frozen clumps left in the infusion bag.
5. Each bag should be gently massaged until the cells have just thawed. Thawing of each infusion bag takes between 2 and 8 minutes and bags should be removed immediately after thawing is complete.
6. Carefully remove the infusion bag from the overwrap taking care to avoid damage to the bag and ports.
7. Gently mix the contents of the bag to disperse clumps of cellular material and administer immediately to the patient using a non-filtered IV giving set as per the instructions below:

a. Bag based Infusion:

1. Prime tubing with normal saline prior to infusion.
2. Administer the AUCATZYL® drug product via a gravity or peristaltic pump assisted IV infusion through a central venous line (or large peripheral venous access line appropriate for blood products).
   - DO NOT USE a leukodepleting filter.
   - Infusion should occur immediately and should be completed no longer than 60 minutes after end of thaw (not including flushing).
   - Aseptic techniques must be applied when performing venipuncture (if applicable), spiking the ports, and through cell administration process.
3. After the entire contents of the bag is infused, flush the bag through with 30mL normal saline.
4. Flush the infusion line with 60 mL of normal saline.

b. Syringe-based Infusion (for the 10x10^6 CAR Positive T cell dose only):

INSTITUTIONAL PROCEDURES MUST BE FOLLOWED WITH REGARD TO SYRINGE LABELLING AND HANDLING TO MAINTAIN CHAIN OF IDENTITY.

1. Use the smallest Luer-lock tip syringe necessary (1, 3, 5, or 10 mL) depending on the dosing volume specified on the Release for Infusion Certificate with a Luer-lock bag spike. A blunt non-filtered 18-gauge needle may be used as an alternative.
2. The volume to be administered for the 10 x 10^6 CD19 CAR-positive T cells dose is specified on the Release for Infusion Certificate. Draw the exact volume as indicated on the Release for Infusion Certificate into the syringe.
   - DO NOT USE a leukodepleting filter.
   - Aseptic techniques must be applied during the syringe filling and AUCATZYL® drug product administration process.
   - DO NOT USE THE SYRINGE TO MIX THE CELLS AS THIS CAN ADVERSELY AFFECT CELL VIABILITY.
3. Prime tubing with normal saline prior to infusion.
4. Administer syringe as an IV infusion as a slow push (approximately 0.5mL/minute) through a central venous line (or large peripheral venous access line appropriate for blood products).
5. Complete infusion at room temperature within 60 minutes after the end of thaw.
6. Flush the infusion line with 60 mL of normal saline.
7. Dispose of any unused portion of AUCATZYL® (according to local biosafety guidelines).

DAY 10 Administration

As AUCATZYL® is administered as a split dose, please repeat referring to the Release for Infusion Certificate and Dose Schedule Planner for available inventory and to determine which cassettes will need to be removed from the controlled-access vapor phase liquid nitrogen storage for the second (Day 10) dose.*

** NOTE: The first AUCATZYL® infusion will take place on Day 1 followed by the second infusion on Day 10 (±2 days). A delay to the 2nd split dose may be required to manage toxicity related to the AUCATZYL® infusion. The infusion can be delayed beyond Day 10 (±2 days) up to Day 21 to allow the adverse event to resolve. Please refer to the AUTOLUS AUCATZYL® Prescribing Information for guidance and/or contact the AutolusAssist™ for additional information.*

Record Drug Product Administration

The drug product infusion dates must be recorded in the AutolusAssist™ Scheduling Portal. Refer to AutolusAssist™ Scheduling Portal User Guide.

Disposal of Waste

Unused portions of AUCATZYL® product and any AUCATZYL® contaminated materials should be disposed of according to local procedures.

Unused or expired product

The Treatment Center should retain any unused AUCATZYL® drug product bags to be stored at ≤ -150°C until they are no longer needed. Any AUCATZYL® drug product that is expired or no longer needed should be disposed of per local procedures.

If a quality issue is identified with any AUCATZYL® drug product the AUCATZYL® drug product should be retained by the site at ≤-150°C and Autolus will provide further instructions.